Literature DB >> 28380424

Association of VEGF and VDR gene- gene and gene- smoking interaction on risk of multiple myeloma in Chinese Han population.

Peng Chen1, Zhen-Lan Du2,3,4, Yuan Zhang1, Bing Liu1, Zhi Guo1, Jin-Xing Lou1, Xue-Peng He1, Hui-Ren Chen1.   

Abstract

AIMS: To investigate the association of several single nucleotide polymorphisms (SNPs) within vascular endothelial growth factor (VEGF) and vitamin D receptor (VDR) gene polymorphisms and additional gene- gene and gene- smoking interaction with multiple myeloma (MM) risk in Chinese population.
METHODS: Generalized multifactor dimensionality reduction (GMDR) was used to screen the best interaction combination among SNPs and smoking. Logistic regression was performed to investigate association between 6 SNPs within VEGF and VDR gene, additional gene- gene and gene- smoking interaction on MM risk.
RESULTS: MM risk is significantly higher in carriers with the rs699947- A allele within VEGF gene than those with CC genotype (CA+ AA versus CC), adjusted OR (95%CI) =1.72 (1.19-2.33), and higher in carriers with rs2228570- T allele within VDR gene than those with CC genotype (CT+ TT versus CC), adjusted OR (95%CI) = 1.68 (1.26-2.17). We also found a significant two-locus model (p=0.0010) involving rs699947 and rs2228570, and a significant two-locus model (p=0.0107) involving rs2228570 andsmoking. Participants with rs699947- CA+AA and rs2228570- CT+TT genotype had the highest MM risk, compared to participants with rs699947- CC and rs2228570- CC genotype, OR (95%CI) = 3.12 (1.82 -4.61). Smokers with rs2228570- CT+TT genotype had the highest MM risk, compared to never- smokers with rs2228570- CC genotype, OR (95%CI) = 3.27 (1.74-4.86).
CONCLUSIONS: We found that the A allele of rs699947 within VEGF and T allele of rs2228570 within VDR gene, interaction between rs699947 and rs2228570, rs2228570 andsmoking were all associated with increased MM risk.

Entities:  

Keywords:  interaction; multiple myeloma; smoking; vascular endothelial growth factor; vitamin D receptor

Mesh:

Substances:

Year:  2017        PMID: 28380424      PMCID: PMC5482672          DOI: 10.18632/oncotarget.16510

Source DB:  PubMed          Journal:  Oncotarget        ISSN: 1949-2553


INTRODUCTION

Multiple myeloma (MM) is a fatal disorder of plasma cells derived from an early precursor of B-cell lineage and is responsible for about 2% of all cancer deaths [1]. The etiology of MM is not well studied until now. Previous evidences suggested that some environmental factors including exposure to radiation, herbicides, insecticides, benzene, and other organic solvents may be risk factors for MM [2]. Recent studies indicated that BMI [3] and alcohol drinking [4] were associated with MM risk. On the other hand, racial differences for MM incidence and familial clusters of the disease indicated that the role of genetic predisposition to MM should be taken seriously [2]. Recent years, some genes related to MM susceptibility have been reported in some studies, including vascular endothelial growth factor (VEGF) gene and vitamin D receptor (VDR) polymorphisms. The VEGF gene is located on chromosome 6p21.3 and consists of 8 exons exhibiting alternate splicing to form a family of proteins [5]. Activation of the VEGF receptors could increase the production of various haematopoietic growth factors, and then stimulate the myeloma cell in a paracrine pathway [6, 7]. The expression of VEGF in response to different stimuli is highly variable among individuals. Single nucleotide polymorphisms (SNPs) in the VEGF gene may contribute to this variation [8]. Some polymorphisms within VEGF have been reported association with some types of cancer, such as rs699947, rs2010963 and rs833061 and so on [9-11]. However, the association between VEGF gene and MM risk were not well verified [12-14]. Vitamin D is a fundamental mediator of skeletal metabolism due to its ability to regulate calcium homeostasis. Its deficiency negatively affects bone mineralization and stimulates osteoclast-mediated bone resorption [15]. Studies have reported low serum vitamin D as an important contributor to the skeletal complications which was a major cause of morbidity in MM [16, 17]. 1, 25(OH) 2 D3 was the hormonal derivative of vitamin D and have growth-regulatory effect through binding to the intranuclear receptor vitamin D receptor (VDR) [18]. Several polymorphisms have been identified in various introns and exons of VDR gene, including ApaI, BsmI and FokI [19], and recent studies have indicated that these SNPs may be linked with many kinds of cancer risks [20-22]. But the association between VDR gene and MM risk were less studied. Smoking was a risk factor for many types of cancer, but to date, no study focused on gene- smoking interaction on MM risk. In consideration of the limited study focused on association of VEGF and VDR gene with MM risk, and these studies concluded inconsistent results. So in current study, we aimed to investigate the association of several SNPs within VEGF and VDR gene and additional gene- gene and gene- smoking interaction with MM risk in Chinese population.

RESULTS

A total of 1388 participants (733 males, 655 females) were selected, including 460 MM patients and 928 control participants. The mean age of all participants was 62.3 ± 14.2 years. Participants characteristics stratified by cases and controls were shown in Table 1. The mean of age and distributions of males and alcohol drinkers were not significantly different between cases and controls. The mean of BMI was higher in controls than cases. The rate of smokers was higher in cases than controls.
Table 1

General characteristics of 1388 study participants in case and control group

VariablesCase group(n=460)Control group(n=928)p-values
Age (year) (Means± SD)62.6±14.561.9±15.80.425
Males, N (%)248 (53.9)485 (52.3)0.562
Smokers, N (%)201 (43.7)257 (27.7)<0.001
Alcohol drinkers, N (%)139 (30.2)246 (26.5)0.146
BMI (kg/m2) (Means± SD)23.1±9.824.6±9.20.005
Family history of MM N (%)43 (9.3)
Staging
  DS I–II108 (23.5)
  DS III352 (76.5)
  ISS I–II276 (60.0)
  ISS III184 (40.0)
Percentage of bone marrow plasma cells (range)35 (14–93)
Creatinine in mg/dl (range)1.7 (0.5–6.1)
C-reactive protein in mg/dl (range)0.6 (0.1–15.8)
All genotypes are distributed according to HWE in controls (all p values are more than 0.05). The frequencies for the rs699947- A allele within VEGF gene and rs2228570- T allele within VDR gene were significantly higher in MM cases than control group (31.2% vs20.3%, 28.8% vs19.5%). Logistic regression analysis showed that MM risk was significantly higher in carriers with the rs699947- A allele within VEGF gene than those with CC genotype (CA+ AA versus CC), adjusted OR (95%CI) =1.72 (1.19-2.33), and higher in carriers with the rs2228570- T allele within VDR gene than those with CC genotype (CT+ TT versus CC), adjusted OR (95%CI) = 1.68 (1.26-2.17). However, we did not find any significant association of the others SNPs in VEGF and VDR gene with MM risk after covariates adjustment. (Table 2)
Table 2

Genotype and allele frequencies of 6 SNPs between case and control group

SNPGenotypes andAllelesFrequencies N (%)OR(95%CI)*HWE test forcontrols
Control (n=928)Case (n=460)
VEGF gene
rs2010963(+405 G>C)
Co-dominant
GG542(58.4)241 (52.4)1.00 (ref)0.935
GC335(36.1)181 (39.3)1.28(0.83-1.87)
CC51(5.5)38 (8.3)1.51(0.79-2.34)
Dominant
GG542(58.4)241 (52.4)1.00 (ref)
GC+CC386(41.6)219(47.6)1.36(0.81-1.96)
Allele, C (%)437(23.5)257(27.9)
rs699947(2578 C>A)
Co-dominant
CC598(64.4)229(49.8)1.00 (ref)0.108
CA284(30.6)175(38.0)1.36(1.08-1.72)
AA46 (5.0)56(12.2)2.38(1.59-3.17)
Dominant
CC598(64.4)229(49.8)1.00 (ref)
CA+AA330(35.6)231(50.2)1.72(1.19-2.33)
Allele, A (%)376(20.3)287(31.2)
rs833061(460 C>T)
Co-dominant
CC532(57.3)236 (51.3)1.00 (ref)0.105
CT329(35.5)177(38.5)1.24 (0.81-1.80)
TT67 (7.2)47(10.2)1.48 (0.86-2.13)
Dominant
CC532(57.3)236 (51.3)1.00 (ref)
CT+TT396(42.7)224(48.7)1.30(0.83-1.91)
Allele, T (%)463(25.0)271(29.5)
VDR gene
ApaI (rs7975232)
Co-dominant
GG537(57.9)238 (51.7)1.00 (ref)0.288
GT330(35.6)175 (38.1)1.24(0.81-1.83)
TT61(6.6)47 (10.2)1.57(0.75-2.40)
Dominant
GG537(57.9)238 (51.7)1.00 (ref)
GT+TT391(42.1)222(48.3)1.26(0.79-1.99)
Allele, T (%)452(24.4)269(29.2)
FokI (rs2228570)
Co-dominant
CC607 (65.4)237 (51.5)1.00 (ref)0.234
CT280 (30.2)181 (39.3)1.47 (1.22-1.85)
TT41 (4.4)42 (9.2)2.12 (1.43-2.88)
Dominant
CC607 (65.4)237 (51.5)1.00 (ref)
CT+TT321 (34.6)223 (48.5)1.68 (1.26-2.17)
Allele, T (%)362 (19.5)265 (28.8)
BsmI (rs1544410)
Co-dominant
AA590 (63.6)259(56.3)1.00 (ref)
AG290 (31.2)161 (35.0)1.32 (0.92-1.81)
GG48 (5.2)40 (8.7)1.52 (0.83-2.35)
Dominant
AA590 (63.6)259(56.3)1.00 (ref)
AG+GG338 (36.4)201 (43.7)1.38 (0.90-1.87)
Allele, G (%)386 (20.8)241 (26.2)

* Adjusted for gender, age, smoking and alcohol status, BMI and WC.

* Adjusted for gender, age, smoking and alcohol status, BMI and WC. Table 3 summarized the results obtained from GMDR analysis. We found a significant two-locus model (p=0.0010) involving rs699947 and rs2228570, indicating a potential interaction between rs699947 and rs2228570 on MM risk. Overall, the cross-validation consistency of this two- locus model was 9/ 10, and the testing accuracy was 60.72%. We also found a significant two-locus model (p=0.0107) involving rs2228570 and smoking, indicating a potential interaction between rs2228570 and smoking on MM risk, Overall, the cross-validation consistency of this two- locus model was 10/ 10, and the testing accuracy was 60.11%.
Table 3

GMDR analysis on the best gene–gene and gene- smoking interaction models

Locus no.Best combinationCross-validationconsistencyTestingaccuracyp-values
Gene- gene interactions*
 2rs699947 rs22285709/100.60720.0010
 3rs699947 rs2228570 rs20109638/100.53990.1719
 4rs699947 rs2228570 rs2010963 rs15444107/100.53990.3770
 5rs699947 rs2228570 rs2010963 rs1544410 rs8330616/100.49580.4258
 6rs699947 rs2228570 rs2010963 rs1544410 rs833061 rs79752325/100.49580.6230
Gene- smoking interactions *
 2rs2228570 Smoking10/100.60110.0107
 3rs2228570 rs699947 Smoking9/100.53990.1719
 4rs2228570 rs699947 rs2010963 Smoking8/100.49580.3770
 5rs2228570 rs699947 rs2010963 rs1544410 Smoking7/100.49580.4258
 6rs2228570 rs699947 rs2010963 rs1544410 rs8330616/100.49580.6230
 7rs2228570 rs699947 rs2010963 rs1544410 rs833061 rs7975232 Smoking5/100.49580.9893

* Adjusted for gender, age, smoking, drinking and BMI for gene- gene interaction analysis

**Adjusted for gender, age, drinking and BMI for gene- smoking interaction analysis

* Adjusted for gender, age, smoking, drinking and BMI for gene- gene interaction analysis **Adjusted for gender, age, drinking and BMI for gene- smoking interaction analysis In the stratified logistic regression, we found that participants with rs699947- CA+AA within VEGF gene and rs2228570- CT+TT genotype within VDR gene had the highest MM risk, compared to participants with rs699947- CC within VEGF gene and rs2228570- CC genotype, OR (95%CI) = 3.12 (1.82 -4.61), after covariates adjustment. We also found that current smokers with rs2228570- CT+TT genotype had the highest MM risk, compared to never- smokers with rs2228570- CC within VDR genotype, OR (95%CI) = 3.27 (1.74-4.86), after covariates adjustment (Table 4).
Table 4

Analysis for gene-gene and gene- smoking interaction by using logistic regression

Variable 1Variable 2OR (95% CI)*P-values
rs699947rs2228570
CCCC1.00-
CA+AACC1.48 (1.14 -1.92)0.001
CCCT+TT1.38 (1.05-1.79)0.032
CA+AACT+TT3.12 (1.82 -4.61)<0.001
rs2228570Smoking
CCNever1.00-
CT+TTNever1.35(1.04 -1.82)0.038
CCCurrent1.56 (1.17-2.01)0.002
CT+TTCurrent3.27 (1.74-4.86)<0.001

* Adjusted for gender, age, drinking and BMI

* Adjusted for gender, age, drinking and BMI

DISCUSSION

In this study, we found that both the A allele of rs699947 within VEGF and T allele of rs2228570 within VDR gene are significantly associated with increased in MM cases. The VEGF gene is located on chromosome 6p21.3 and consists of 8 exons exhibiting alternate splicing to form a family of proteins[4]. Some studies [9-11] have reported that several SNPs within VEGF were associated with some types of cancer, such as oral, breast, glioma, colorectal and lung. However, the association between VEGF gene and MM risk has not been interpreted so far, and less studies focused on this relationship previously [12-14]. Andersen et al [12] suggested that the VEGF haplotype ACG may influence the efficacy of thalidomide treatment in patients with multiple myeloma, although they did not find any association between SNP and MM risk. Another study [13] also did not find relationship between SNP within VEGF gene and MM risk, however they indicated that VEGF and GST genotypes can combine to influence the risk for MM in south-eastern Brazil. Brito et al [14] also suggested that inherited abnormalities in VEGF (−2578C/A, −1154G/A, −634G/C) pathways influence the risk and aggressiveness of MM, relatively small sample size may be the main reason for the negative result obtained in these studies. Berardi [23] et al firstly indicated that inherited abnormalities in VEGFR-3 pathways influence the risk and aggressiveness of thymic epithelial tumors (TETs). VDR is encoded by a large gene (>100 kb) located on chromosome 12cen-q12 containing 14 exons. BsmI (rs1544410), ApaI (rs7975232) and FokI (rs2228570) were three common SNPs in VDR gene polymorphism. Studies have reported low serum vitamin D as an important contributor to the skeletal complications which is a major cause of morbidity in MM [16, 17]. Several polymorphisms have been identified in various introns and exons of VDR gene most commonly ApaI, BsmI and FokI [19], and recent studies [20-22] have indicated that these SNPs may be linked with many kinds of cancer risks. To date, just one population based study [24] was conducted to investigate the association between VDR SNPs and MM risk. In this study, the authors indicated that the FokI polymorphism was associated increased susceptibility to MM in the ethnic Kashmiri population. MM susceptibility was influenced by both genetic and environment factors, and previously several environmental factors associated with MM were reported, including exposure to radiation, herbicides, insecticides, benzene and other organic solvents may be risk factors for MM [2]. Cigarette smoking has been suggested to play a crucial role in increasing the risk of some types of cancer risk, but the association with MM risk was inconclusive [25, 26]. In current study, we found that the smoking rate was higher in MM cases than controls, it means that smoking may be positively associated with MM risk, so in this study we investigated not only gene- gene interaction, but also gene- environment interaction between SNPs and smoking. We found a potential interaction between rs699947 and rs2228570 and a potential interaction between rs2228570 andsmoking on MM risk, participants with rs699947- CA+AA within VEGF gene and rs2228570- CT+TT genotype within VDR gene had the highest MM risk, compared to participants with rs699947- CC within VEGF gene and rs2228570- CC genotype, in addition, current smokers with rs2228570- CT+TT genotype also had the highest MM risk, compared to never- smokers with rs2228570- CC within VDR genotype. There several limitations in our study. Firstly, more SNPs within VEGF and VDR gene should been included in the analysis, not only for just 6 SNPs. Secondly, some others environmental risk factors should be investigated in the gene- environment interaction analysis. Thirdly, the results obtained from our study should be checked in the future studies. In conclusion, we found that the A allele of rs699947 within VEGF and T allele of rs2228570 within VDR gene, interaction between rs699947 and rs2228570, rs2228570 andsmoking were all associated with increased MM risk.

MATERIALS AND METHODS

Subjects

All study participants were recruited between June 2008 and March 2015 from the PLA Army General Hospital. The diagnostic criteria for MM have been described elsewhere and the clinical staging system for MM that was used according to International Myeloma Working Group criteria [27]. Controls were randomly selected from healthy volunteers from community-based chronic non-communicable diseases screening program conducted with a 1:2 matched (age and sex) in the same region. Consequently, a total of 460 newly diagnosed MM cases and 928 control participants were included in current study. The mean age of all participants is 62.3 ± 14.2 years. Questionnaire investigation was conducted for all participants, and data on demographic information, clinical and biochemical index for all participants were obtained. Body weight and height were measured. Body mass index (BMI) was calculated as weight in kilograms divided by the square of the height in meters. Current cigarette smokers were those who self-reported smoking cigarettes at least once a day for 1 year or more. Alcohol consumption was expressed as the sum of milliliters of alcohol per week from wine, beer, and spirits. Blood samples were collected from each participant in the morning after at least 8 hours of fasting. Informed consent was obtained from all participants.

Genomic DNA extraction and genotyping

The SNPs were selected based on the NCBI database (http://www.ncbi.nlm.nih.gov/projects/SNP) according to the following three criteria: 1) located in a gene fragment that could have functional effects, and 2) with a minor allele frequency (MAF) of at least 5%, 3) previously reported associations with any type of cancer. Taking into account the limited human resources and financial resources, a total of 3 SNPs within VEGF and 3 SNPs within VDR gene were selected for genotyping, including: rs699947, rs2010963 and rs833061 within VEGF gene, rs2228570, rs1544410 and rs7975232 within VDR gene. Genomic DNA from participants was extracted from EDTA-treated whole blood, using the DNA Blood Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions and stored at -20°C until use. The genotypes of six SNPs were detected by polymerase chain reaction-restriction fragment length polymorphism (PCR–RFLP) method. The nucleotide sequence of primers and description for the 6 SNPs were shown in Table 5. Genotyping for VEGF SNPs: In each 0.20-mL PCR reaction tube, 1 μL of genomic DNA (100 ng/mL), 1 μL of each primer (10 μM), 10 μL of 2X Prime Taq Premix, and appropriate amount of ddH2O were added. The PCR-cycling conditions: 5 minutes at 95°C, followed by 30 cycles of 30 seconds at 95°C, 30 seconds at 62°C for rs2010936, 63°C for rs3025039 and rs833061, 61°C for rs699947, 60°C for rs35569394, and 30 seconds at 72°C with a final extension step of 72°C for 5 min. Genotyping for VDR SNPs: The reaction volume was 25 mL, containing a Mastermix containing Taq DNA polymerase, dNTPs mix and reaction buffer (Shanghai, China). A total of 0.5μM of each primer, 2μl of template cDNA, 9μl 2.5* Mastermix, and 8.5μl distilled water, (ddH2O) were used in all reactions (in triplicate). Amplification and detection were carried out as follows. The protocol (denaturation 95°C, 15 s; annealing 60°C, 60 s; elongation 72°C, 45 s) consisted of 40 cycles to ensure a linear range of the PCR reaction.
Table 5

Description and probe sequence for 6 SNPs used for PCR analysis

SNP IDChromosomeFunctionalConsequenceRestrictionenzymeNucleotidesubstitutionPrimer sequences
VEGF gene
rs2010963+405 G>C6:43770613Upstream variant 2KB, utr variant 5 primeFaqIG > CF:5′-TTGCTTGCCATTCCCCA CTTGA-3′R: 5′-CCGAAGCGAGAACAGC CCAGA-3′
rs833061460 C>T6:43769749Upstream variant 2KBHinpIC>TF:5′-TGAGTGTGTGCGTGTGGG GTTGAGCG-3′R: 5′-AGAGCCGTTCCCTCTTT GCTAG-3′
rs6999472578 C>A6:43768652Upstream variant 2KBBstyIC>AF:5′-GGCCTTAGGACACCATACC-3′R: 5′-CACAGCTTCTCCCCTATCC-3′
VDR gene
FokI (rs2228570)12:47879112MissenseFokIC>TForward: GCACTGACTCTGGC TCTGACReverse: ACCCTCCTGCTCCT GTGGCT
BsmI (rs1544410)12:47846052Intron variant, upstream variant 2KBFspIA>GForward: GGAGACACAGATAA GGAAATACReverse: CCGCAAGAAACCTCAA ATAACA
ApaI (rs7975232)12:47845054Intron variant, upstream variant 2KBApaIG>TForward: TGGGCACGGGGATAG AGAAGReverse: ACGGAGAAGTCACTG GAGGG
Genotyping results were confirmed by randomly assaying 10% of the original specimens for replication to exclude genotyping errors. There were no discrepancies between genotypes determined in duplicate.

Statistical analysis

All statistical analyses were performed using the SPSS 22.0 software package (SPSS Inc, Chicago) for Windows 7. The means and SDs were calculated for normally distributed continuous variables and were compared by Student's t test, and percentages were calculated for categorical variables and were analyzed using χ2 test. Departure from Hardy-Weinberg equilibrium (HWE) in controls was tested using SNPstats (http://bioinfo.iconcologia.net/SNPstats). Generalized multifactor dimensionality reduction (GMDR) was used to screen the best interaction combination among SNPs and smoking. Logistic regression was performed to investigate association of 6 SNPs within VEGF and VDR gene, additional gene- gene and gene- smoking interaction with MM risk. All reported p-values were two-tailed, and those less than 0.05 were considered statistically significant.
  27 in total

1.  Significance of vitamin D receptor gene polymorphism for prostate cancer risk in Japanese.

Authors:  M Watanabe; K Fukutome; M Murata; H Uemura; Y Kubota; J Kawamura; R Yatani
Journal:  Anticancer Res       Date:  1999 Sep-Oct       Impact factor: 2.480

2.  Associations of VEGF and VEGFR2 polymorphisms with increased risk and aggressiveness of multiple myeloma.

Authors:  Angelo Borsarelli Carvalho Brito; Gustavo Jacob Lourenço; Gislaine Borba Oliveira; Cármino Antônio De Souza; José Vassallo; Carmen Silvia Passos Lima
Journal:  Ann Hematol       Date:  2014-04-01       Impact factor: 3.673

Review 3.  Vitamin D deficiency.

Authors:  Michael F Holick
Journal:  N Engl J Med       Date:  2007-07-19       Impact factor: 91.245

4.  Prevalence and significance of vitamin D deficiency in multiple myeloma patients.

Authors:  Ashraf Badros; Olga Goloubeva; Evangelos Terpos; Todd Milliron; Maria R Baer; Elizabeth Streeten
Journal:  Br J Haematol       Date:  2008-05-08       Impact factor: 6.998

5.  Cloning and expression of full-length cDNA encoding human vitamin D receptor.

Authors:  A R Baker; D P McDonnell; M Hughes; T M Crisp; D J Mangelsdorf; M R Haussler; J W Pike; J Shine; B W O'Malley
Journal:  Proc Natl Acad Sci U S A       Date:  1988-05       Impact factor: 11.205

6.  Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma.

Authors:  B Dankbar; T Padró; R Leo; B Feldmann; M Kropff; R M Mesters; H Serve; W E Berdel; J Kienast
Journal:  Blood       Date:  2000-04-15       Impact factor: 22.113

7.  Vascular endothelial growth factor polymorphisms in relation to breast cancer development and prognosis.

Authors:  Qianren Jin; Kari Hemminki; Kerstin Enquist; Per Lenner; Ewa Grzybowska; Rüdiger Klaes; Roger Henriksson; Bowang Chen; Jolanta Pamula; Wioletta Pekala; Helena Zientek; Jadwiga Rogozinska-Szczepka; Beata Utracka-Hutka; Göran Hallmans; Asta Försti
Journal:  Clin Cancer Res       Date:  2005-05-15       Impact factor: 12.531

8.  VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death.

Authors:  Diether Lambrechts; Erik Storkebaum; Masafumi Morimoto; Jurgen Del-Favero; Frederik Desmet; Stefan L Marklund; Sabine Wyns; Vincent Thijs; Jörgen Andersson; Ingrid van Marion; Ammar Al-Chalabi; Stephanie Bornes; Rhiannon Musson; Valerie Hansen; Lars Beckman; Rolf Adolfsson; Hardev Singh Pall; Hervé Prats; Severine Vermeire; Paul Rutgeerts; Shigehiro Katayama; Takuya Awata; Nigel Leigh; Loïc Lang-Lazdunski; Mieke Dewerchin; Christopher Shaw; Lieve Moons; Robert Vlietinck; Karen E Morrison; Wim Robberecht; Christine Van Broeckhoven; Désiré Collen; Peter M Andersen; Peter Carmeliet
Journal:  Nat Genet       Date:  2003-08       Impact factor: 38.330

Review 9.  Alcohol drinking and multiple myeloma risk--a systematic review and meta-analysis of the dose-risk relationship.

Authors:  Matteo Rota; Lorenzo Porta; Claudio Pelucchi; Eva Negri; Vincenzo Bagnardi; Rino Bellocco; Giovanni Corrao; Paolo Boffetta; Carlo La Vecchia
Journal:  Eur J Cancer Prev       Date:  2014-03       Impact factor: 2.497

10.  Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group.

Authors: 
Journal:  Br J Haematol       Date:  2003-06       Impact factor: 6.998

View more
  2 in total

1.  Incidence and Risk Factors of Osteonecrosis of Femoral Head in Multiple Myeloma Patients Undergoing Dexamethasone-Based Regimens.

Authors:  Xinjie Wu; Chuanying Geng; Wei Sun; Mingsheng Tan
Journal:  Biomed Res Int       Date:  2020-05-16       Impact factor: 3.411

Review 2.  Reviewing the Significance of Vitamin D Substitution in Monoclonal Gammopathies.

Authors:  Vanessa Innao; Alessandro Allegra; Lia Ginaldi; Giovanni Pioggia; Massimo De Martinis; Caterina Musolino; Sebastiano Gangemi
Journal:  Int J Mol Sci       Date:  2021-05-06       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.